1. Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

2. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Supplementary <LINK BD >Figure 1 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Supplementary <LINK BD >Figure 1 </LINK>. Progression-free and overall survival in subgroups of patients.1A. Progression-free survival according to gender (blue, female; red, male)1B. Survival according to gender (blue, female; red, male)1C. Progression-free survival in patients with L858R according to gender (blue, female; green, male)1D. Survival according to ECOG PS (blue, PS0; red, PS1; green, PS2)1E. Progression-free survival in patients with L858R according to age (blue, <60; green, 60-70; red, >70)1F. Survival in patients with L858R according to age (blue, <60; green, 60-70; red, >70)1G. Progression-free survival in PS1 patients according to gender (blue, female; green, male)1H. Survival in PS1 patients according to gender (blue, female; green, male)

3. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Supplementary <LINK BD >Figure 2 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Supplementary <LINK BD >Figure 2.</LINK> Progression-free (2A) and overall (2B) survival according to response (blue, CR; red, PR; brown, SD; green, PD)

4. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Table 1 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 1 (Supplementary Appendix). Patient characteristics according to gender

5. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Table 2 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 2 (Supplementary Appendix). Patient characteristics according to smoking history

6. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Table 3 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 3 (Supplementary Appendix). Patient characteristics according to age

7. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Table 4 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 4 (Supplementary Appendix). Patient characteristics according to ECOG PS

8. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 8 Table 5 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 5 (Supplementary Appendix). Patient characteristics according to treatment line

9. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 9 Table 6 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 6 (Supplementary Appendix). Metastatic sites

10. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 10 Table 7 Supplement to: Screening for epidermal growth factor receptor mutations in lung cancer. Rosell, R; Moran, T; Queralt, C New England Journal of Medicine. 361(10), September 3, 2009. Table 7 (Supplementary Appendix). Toxicities